Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations.

MLA

Cocciolone, Valentina, et al. “Neoadjuvant Chemotherapy in Breast Cancer: A Dose-Dense Schedule in Real Life and Putative Role of PIK3CA Mutations.” Oncotarget, vol. 9, no. 44, June 2018, pp. 27380–96. EBSCOhost, https://doi.org/10.18632/oncotarget.25270.

APA

Cocciolone, V., Cannita, K., Tessitore, A., Mastroiaco, V., Rinaldi, L., Paradisi, S., Irelli, A., Baldi, P. L., Sidoni, T., Ricevuto, E., Dal Mas, A., Calvisi, G., Coletti, G., Ciccozzi, A., Pizzorno, L., Resta, V., Bafile, A., Alesse, E., & Ficorella, C. (2018). Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations. Oncotarget, 9(44), 27380–27396. https://doi.org/10.18632/oncotarget.25270

Chicago

Cocciolone, Valentina, Katia Cannita, Alessandra Tessitore, Valentina Mastroiaco, Lucia Rinaldi, Stefania Paradisi, Azzurra Irelli, et al. 2018. “Neoadjuvant Chemotherapy in Breast Cancer: A Dose-Dense Schedule in Real Life and Putative Role of PIK3CA Mutations.” Oncotarget 9 (44): 27380–96. doi:10.18632/oncotarget.25270.